Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

SELL
$5.63 - $8.27 $7,133 - $10,478
-1,267 Reduced 95.77%
56 $0
Q3 2023

Nov 14, 2023

BUY
$6.71 - $11.83 $8,877 - $15,651
1,323 New
1,323 $8,000
Q2 2022

Aug 09, 2022

BUY
$13.15 - $20.45 $144 - $224
11 Added 84.62%
24 $0
Q4 2021

Feb 01, 2022

BUY
$20.24 - $36.01 $263 - $468
13 New
13 $0

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $266M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.